Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

NCT02745470 · Completed

Last updated 2026-05-28

This clinical trial is testing how a GLP-1 receptor agonist affects brain activity in people with diabetes by measuring changes in blood oxygen levels.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind basic-science study

Participants 30 people

Who can join Ages 19–70 · all sexes

Timeline Started 2016-02 · est. completion 2016-12

Where 1 site · South Korea

What this study is testing ClinicalTrials.gov NCT02745470 ↗

Description as written by the study sponsor.

The aims this study is to explore the effect of a GLP-1 receptor agonist on the degree of brain activation and connectivity obtained by functional magnetic resonance imaging in lean and obese type 2 diabetes

Treatments tested

Lixisenatide also known as Lyxumia® pen injection Drug

Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
Placebo also known as Normal saline injection Other

Normal saline injection before performing fMRI

Main thing measured	Difference of BOLD (Blood oxygenation level-dependent) signal in hypothalamus
Sponsor	Seoul National University Hospital
Conditions studied	Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02745470 ↗